Phase 1 Study of GEN0101 in Patients With Recurrence of CRPC

Castration Resistant Prostate Cancer Clinical Trial

Official title:

Phase 1 Dose-escalation, Safety / Tolerability and Preliminary Efficacy Study of Intratumoral and Subcutaneous Administration of GEN0101 in Patients With Recurrence of Castration Resistant Prostate Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02502994
• Other study ID #: GEN0101-JM002
• Status: Recruiting
• Phase: Phase 1
• First received: May 12, 2015
• Last updated: July 16, 2015
• Start date: May 2015

Study information

• Verified date: July 2015
• Source: Osaka University
• Contact: Norio Nonomura, MD
• Phone: +81668793531
• Email: nono[@]uro.med.osaka-u.ac.jp
• Is FDA regulated: No
• Health authority: Japan: Pharmaceuticals and Medical Devices Agency
• Study type: Interventional

Clinical Trial Summary

This study is designed to evaluate the safety and efficacy of a single injection of GEN0101 in patients with recurrence of castration resistant prostate cancer.

The subjects receive GEN0101 injection 4 times per two weeks (1st intratumoral injection and followed subcutaneous injection) and two weeks of observation as one cycle treatment period. Each subject receive two cycle treatment period.

Low dose group: 30,000m NAU per injection of GEN0101 High dose group: 60,000m NAU per injection of GEN0101 Each group included minimal 3 subjects.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 12
• Est. primary completion date: December 2016
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 20 Years to 85 Years

Eligibility

Inclusion Criteria:

1. Patients providing a written informed consent by voluntary agreement.

2. Age 20 =< and =<85 years old at the time of informed consent

3. Have a diagnosis of malignant tumor as confirmed by histology or cytology.

4. Have a diagnosis of recurrence of castration resistant prostate cancer and meet the following condition

• Inapplicable to the standard treatment, ineffective through the criteria of the Prostate Cancer Clinical Trials Working Group (PCWG2) or refuse the standard treatment

• More than 6 week between the end date of the standard treatment and the registration date when the standard treatment has been ineffective

5. Serum PSA <100 ng/mL at the screening visit

6. Expected survival period is more than 8 weeks after planned start date of investigational product

7. ECOG Performance Status 0 or 1

8. Have an injectable intraprostatic lesion confirmed by histologic examination

9. The marrow function, liver function and the kidney function must be kept as follows at the screening visit (1) leukocyte >= 3,000/mcL (2) neutrophil >=1,500/mcL (3) platelet >=75,000/mcL (4) hemoglobin >=8.0 g/dL. (5) AST =<100 IU/L (6) ALT =<100 IU/L (7) total bilirubin =<2.5 mg/dL (8) serum creatinine =<2.5 mg/dL

Exclusion Criteria:

1. Have multiple brain metastases

2. Positive result of the prick test of GEN0101

3. Have serious complications such as uncontrolled active infection

4. Received systemic chemotherapy, radiotherapy or immunotherapy within 6 weeks before the planned registration date However the hormone therapy except for the estramustine, enzalutamide and abiraterone, bisphosphonate and anti-RANKL antigen antibody is are not included in the systemic chemotherapy.

5. Received another investigational medical product within 4 weeks before the informed concent

6. Had a history of malignancy other than prostate cancer, except for the relapse-free and metastasis-free for more than 5 years after the last treatment at the registration

7. Have an active autoimmune disease

8. Receiving systemic administration of glucocorticosteroid which restrains immunity response, except for the administration for a long period (over 6 months) of the low dose (equivalent to under 10 mg/day oral prednisolone).

9. Had a history of the autologous or homogeneous organ or tissue transplantation (Receiving immunosuppressive medication)

10. PT(%) less than 10% of the lower limit of normal or APTT more than 1.5 times of the upper limit of normal of local reference range at the screening visit

11. Positive result of the hepatitis B surface antigen, HCV antibody or HIV test at the screening visit

12. Inappropriate to be enrolled in this study judged by the investigators

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Castration Resistant Prostate Cancer
• Prostatic Neoplasms

Intervention

Drug:
• GEN0101

Locations

Country	Name	City	State
Japan	Urology, Osaka University Hospital	Suita	Osaka

Sponsors (1)

Lead Sponsor	Collaborator
Norio Nonomura

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	DLT (Dose Limiting Toxicity)	To determine the appropriate dosing strategy for GEN0101 for castration resistant prostate cancer	8 weeks	No
Secondary	Number of participants with tumor shrinkage according to the RECIST.		8 weeks	No
Secondary	Change from baseline in tumor marker (PSA: Prostate Specific Antigen, NSE: Neuron-specific enolase, CEA: Carcinoembryonic Antigen, and CA19-9: Carbohydrate Antigen19-9) at Cycle 1, Week 4 and at Cycle 2, Week 4.		8 weeks	No
Secondary	Change from baseline in prostate histological evaluation at Cycle2, Week2.		8 weeks	No
Secondary	Change from baseline in induction of antitumor immunity (NK cell activity, IL-6 and IFN-gamma) at Cycle1, Week 2 and Week 4 and at Cycle2, Week 2 and Week 4.		8 weeks	No